Dongsung Pharmaceutical Co. Ltd. announced that it has received KRW 10 billion in funding from Synergy Partners Co., Ltd., Golden Bridge Asset Management Co., Ltd., Susung Asset Management Co., Ltd., NH Investment & Securities Co., Ltd., Investment Arm
July 12, 2016
Share
On July 12, 2016, Dongsung Pharmaceutical Co. Ltd. (KOSE:A002210) closed the transaction.
Dongsung Pharmaceutical Co., Ltd. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include anti-rheumatic, anti-inflammatory analgesics, anti-inflammatory enzymes, drugs for cardiovascular system, gastrointestinal drugs, antispasmodic agents, respiratory agents, anti-histamine, dermatologicals, antibiotics, antidiarrheals, antifungals, oral hypoglycemic agents, hormones, hypnotics and others. It also produces hair dyes and cosmetics. The Company distributes its products within domestic market and to overseas markets.
Dongsung Pharmaceutical Co. Ltd. announced that it has received KRW 10 billion in funding from Synergy Partners Co., Ltd., Golden Bridge Asset Management Co., Ltd., Susung Asset Management Co., Ltd., NH Investment & Securities Co., Ltd., Investment Arm